Outlook Therapeutics, Inc.
-
Ticker
OTLK
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 11-50 Employees
- Based in Cranbury, New Jersey
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation
…More of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
Outlook Therapeutics, Inc.
Most Recent Annual Report
MOST RECENT
2020 Annual Report and Form 10K
Older/Archived Annual Reports